193 related articles for article (PubMed ID: 16797393)
21. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Zisman AL; Ghantous W; Schinleber P; Roberts L; Sprague SM
Am J Nephrol; 2005; 25(6):591-5. PubMed ID: 16282676
[TBL] [Abstract][Full Text] [Related]
23. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud H; Coyne D; Smolenski O; Anger M; Lunde N; Qiu P; Hippensteel R; Pradhan RS; Palaparthy RV; Kavanaugh A; Melnick JZ; Williams LA; Batlle D
Am J Nephrol; 2006; 26(1):105-14. PubMed ID: 16543714
[TBL] [Abstract][Full Text] [Related]
24. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Llach F; Keshav G; Goldblat MV; Lindberg JS; Sadler R; Delmez J; Arruda J; Lau A; Slatopolsky E
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
[TBL] [Abstract][Full Text] [Related]
25. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
27. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
[TBL] [Abstract][Full Text] [Related]
28. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach F; Yudd M
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
Lund RJ; Andress DL; Amdahl M; Williams LA; Heaney RP
Am J Nephrol; 2010; 31(2):165-70. PubMed ID: 20016142
[TBL] [Abstract][Full Text] [Related]
30. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
[TBL] [Abstract][Full Text] [Related]
31. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
32. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
[TBL] [Abstract][Full Text] [Related]
33. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients.
Zanos S; Mitsopoulos E; Sakellariou G
Ren Fail; 2005; 27(2):163-9. PubMed ID: 15807180
[TBL] [Abstract][Full Text] [Related]
35. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
36. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
Martin KJ; González E; Lindberg JS; Taccetta C; Amdahl M; Malhotra K; Llach F
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S57-63. PubMed ID: 11689389
[TBL] [Abstract][Full Text] [Related]
37. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
Moe SM; Zekonis M; Harezlak J; Ambrosius WT; Gassensmith CM; Murphy CL; Russell RR; Batiuk TD
Am J Kidney Dis; 2001 Oct; 38(4):792-802. PubMed ID: 11576883
[TBL] [Abstract][Full Text] [Related]
38. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030
[TBL] [Abstract][Full Text] [Related]
39. Assessing the impact of low baseline parathyroid hormone levels on surgical treatment of primary hyperparathyroidism.
Clark MJ; Pellitteri PK
Laryngoscope; 2009 Jun; 119(6):1100-5. PubMed ID: 19418534
[TBL] [Abstract][Full Text] [Related]
40. Stricter criteria increase the validity of a quick intraoperative parathyroid hormone assay in primary hyperparathyroidism.
Lupoli GA; Fonderico F; Panico A; Del Prete M; Marciello F; Granieri L; Manguso F; Misso C; Marzano LA; Lupoli G
Med Sci Monit; 2009 Mar; 15(3):CR111-6. PubMed ID: 19247241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
